{'52WeekChange': 1.8236222,
 'SandP52WeekChange': None,
 'address1': '5964 La Place Court',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 17.39,
 'askSize': 800,
 'averageDailyVolume10Day': 1145737,
 'averageVolume': 2544514,
 'averageVolume10days': 1145737,
 'beta': 3.049299,
 'beta3Year': None,
 'bid': 16.75,
 'bidSize': 3100,
 'bookValue': 0.212,
 'category': None,
 'circulatingSupply': None,
 'city': 'Carlsbad',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 17.77,
 'dayLow': 16.43,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -42.963,
 'enterpriseToRevenue': 10.165,
 'enterpriseValue': 1069690240,
 'exDividendDate': None,
 'exchange': 'NGM',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '760 448 4301',
 'fiftyDayAverage': 14.582571,
 'fiftyTwoWeekHigh': 19.83,
 'fiftyTwoWeekLow': 3.36,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 58553187,
 'forwardEps': -0.26,
 'forwardPE': -64.61539,
 'fromCurrency': None,
 'fullTimeEmployees': 437,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.04697,
 'heldPercentInstitutions': 0.91797996,
 'industry': 'Medical Devices',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/genmarkdx.com',
 'longBusinessSummary': 'GenMark Diagnostics, Inc., a molecular diagnostics '
                        'company, develops and commercializes molecular panels '
                        'based on its proprietary eSensor electrochemical '
                        'detection technology. It provides ePlex instrument '
                        'and respiratory pathogen panel, which integrates '
                        'automated nucleic acid extraction and amplification '
                        'with its eSensor technology to enable operators using '
                        'ePlex system to place patient sample directly into '
                        'its test cartridge and obtain results. The company '
                        'offers XT-8 instrument, and related diagnostic and '
                        'research tests, as well as certain custom '
                        'manufactured reagents to support a range of molecular '
                        'tests with a workstation and disposable test '
                        'cartridges. It also provides diagnostic tests for use '
                        'with its XT-8 system that includes respiratory viral '
                        'panel, cystic fibrosis genotyping test, thrombophilia '
                        'risk test, a warfarin sensitivity test, and hepatitis '
                        'C virus genotyping test and associated custom '
                        'manufactured reagents, as well as 2C19 genotyping '
                        'test. The company sells its products through direct '
                        'sales and technically specialized service '
                        'organization in the United States and Europe. GenMark '
                        'Diagnostics, Inc. is headquartered in Carlsbad, '
                        'California.',
 'longName': 'GenMark Diagnostics, Inc.',
 'market': 'us_market',
 'marketCap': 1179890816,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_92870',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -42278000,
 'nextFiscalYearEnd': 1640908800,
 'open': 17.77,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': 0.97,
 'phone': '760 448 4300',
 'previousClose': 17.93,
 'priceHint': 2,
 'priceToBook': 79.24528,
 'priceToSalesTrailing12Months': 11.212495,
 'profitMargins': -0.40177,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 17.77,
 'regularMarketDayLow': 16.43,
 'regularMarketOpen': 17.77,
 'regularMarketPreviousClose': 17.93,
 'regularMarketPrice': 17.77,
 'regularMarketVolume': 938241,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 70231600,
 'sharesPercentSharesOut': 0.1014,
 'sharesShort': 7118329,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 4341190,
 'shortName': 'GenMark Diagnostics, Inc.',
 'shortPercentOfFloat': 0.117,
 'shortRatio': 3.34,
 'startDate': None,
 'state': 'CA',
 'strikePrice': None,
 'symbol': 'GNMK',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -0.721,
 'twoHundredDayAverage': 8.705899,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': '430211ba-81c6-3dbc-8576-653bc4c173a2',
 'volume': 938241,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.genmarkdx.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '92008-8829'}